Title : Genomic disruption of the NRXN1 gene: Implications for synaptic biology and neuropsychiatric disorders
Abstract:
Advances in high‑resolution genomic technologies—including chromosomal microarray, next‑generation sequencing, and targeted CNV assays—have substantially enhanced our ability to detect clinically meaningful structural variation in patients with suspected neurodevelopmental and neuropsychiatric disease. Within this landscape, deletions involving the NRXN1 gene have emerged as among the most recurrent and consequential findings encountered in clinical cytogenomic testing. As a presynaptic cell‑adhesion molecule essential for synapse assembly and neurotransmission, NRXN1 plays a central role in neural circuit formation. A synthesis of 173 published studies demonstrates that NRXN1 haploinsufficiency is consistently associated with autism spectrum disorder, global developmental delay, speech and language impairment, epilepsy, and schizophrenia, while rare biallelic losses produce severe phenotypes resembling Pitt–Hopkins–like syndromes.
From a mechanistic perspective, NRXN1-related disease largely reflects disruption of trans‑synaptic signaling within neurexin–neuroligin pathways, which are critical for maintaining excitatory–inhibitory balance and synaptic plasticity. Exonic deletions involving the 5′ region and α‑isoform promoter show the strongest functional effects and highest penetrance. Yet, in routine clinical practice, the phenotypic expression of NRXN1 deletions is strikingly variable—ranging from asymptomatic parental carriers to profound neurocognitive impairment in affected children—underscoring the need for careful interpretation within a broader genomic and clinical context.
These observations reinforce the importance of including NRXN1 in diagnostic microarray and sequencing workflows, especially for patients presenting with early developmental delays, ASD features, unexplained epilepsy, or psychiatric symptoms. Given the incomplete penetrance and frequent presence of additional contributing variants, genetic counseling must emphasize variable expressivity. Collectively, current evidence positions NRXN1 as a key node in neurodevelopmental circuitry and a high‑yield target for diagnostic evaluation, mechanistic investigation, and future therapeutic refinement. As the field advances toward precision‑based frameworks, a deeper understanding of NRXN1 biology will be essential for improving diagnostic accuracy, prognostic clarity, and individualized patient management across the lifespan.
